Abstract
BackgroundThe use of molecular targeted therapies has improved the clinical course and quality of life of patients with rheumatoid arthritis (RA); however, a percentage of patients experience treatment failure (non-responders),...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
